As more of your hospital and surgeon customers embrace value-based healthcare, it is imperative to understand how you play a role in this reimbursement shift.

Advancements in orthobiologics have effects across all market segments. We asked Andy Carter, Ph.D., Chief Technology Officer at TheraCell, to give his insight on the orthobiologics market—as it stands now, and where it’s heading tomorrow. 
Available for download:
And, don't miss your copy of THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT ® !

We spoke with David Kay, M.D., a foot and ankle surgeon and entrepreneur, to hear what he thinks about current and future factors affecting trauma.

At OMTEC ® 2019, surgeons were clear: they are interested in leveraging innovations in materials, robotics, AI and wearables for the benefit of their patients and their practices. They will look to the data to measure progress.

NuVasive capitalized on the advantages of AM, going from design to market in just over one year with the 2017 launch of Modulus—now a full implant line.

Visit ORTHOWORLD in Booth 1726
We'll have a comfortable chair, a cold drink and an ear for your challenges.
Prefer to schedule in advance? Contact Fran Bursic.
From the Archives:


This month's articles on value analysis, biologic development and device distribution brought to mind last year's discussion with Patrick Sweeney, M.D. Revisit the diverse interests of this surgeon inventor.
This eNewsletter is published by ORTHOWORLD Inc. and is available to Members of ORTHOWORLD or by email subscription . Copyright © 2019. All rights reserved.

Carolyn LaWell, Chief Content Officer | carolyn@orthoworld.com
Julie A. Vetalice, Editorial Assistant | julie@orthoworld.com